Education
About Us
Working with TipRanks
Follow Us
Imugene (AU:IMU)
ASX:IMU
IMU Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.25 - AU$1.87
Previous CloseN/A
Volume11.90M
Average Volume (3M)2.02M
Market Cap
$90.23M
Enterprise ValueAU$85.79M
Total Cash (Recent Filing)$33.74M
Total Debt (Recent Filing)$15.76M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Mar 04, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding295,832,950
10 Day Avg. Volume2,408,907
30 Day Avg. Volume2,018,360
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue68.19
Enterprise Value/Gross Profit68.19
Enterprise Value/Ebitda-0.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering0
Imugene News
IMU FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest share price was AU$0.24 and its highest was AU$1.87 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is $90.23M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Mar 04, 2026 which is in 163 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Aug 27, 2025. The company reported -AU$0.094 earnings per share for the quarter, beating the consensus estimate of -AU$0.34 by AU$0.246.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Overvalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate is -0.34.
How many shares outstanding does Imugene have?
Imugene has 295,832,950 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -AU$0.094 in its last earnings report, beating expectations of -AU$0.34. Following the earnings report the stock price went up 3.846%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in AU:IMU
Imugene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
AU:IMU Sentiment 78%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.03%
12-Months-Change
Fundamentals
Return on Equity
-83.09%
Trailing 12-Months
Asset Growth
-45.82%
Trailing 12-Months
Company Description
Imugene
Imugene Limited (IMU) is a clinical-stage immuno-oncology company headquartered in Australia, focusing on the development of novel therapies that enhance the body's immune system to fight cancer. The company specializes in developing a range of immunotherapy products, including oncolytic virotherapy and small molecule immunotherapy, designed to activate and harness the immune system to target and eradicate tumors.
Technical Analysis
Paradigm Biopharmaceuticals
―
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---